Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers

Purpose Fuzuloparib (AiRuiYi TM , formerly fluzoparib, SHR3162) is a new orally active poly adenosine diphosphate ribose polymerase (PARP) inhibitor. It has multiple pharmacological activities in breast, ovarian, and prostatic cancer. Fuzuloparib is mainly metabolized through the enzyme CYP3A4 may s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 89; H. 1; S. 141 - 148
Hauptverfasser:	Chen, Xue, Yang, Feng, Zhao, Jiao, Tang, Qi, Heng, Jianfu, Deng, Jun, Zhang, Jin, Chen, Yong, Li, Kunyan, Wang, Jing
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2022 Springer Nature B.V
Schlagworte:	Adenosine Adult Antifungal agents Aspartate transaminase Breast cancer Cancer Research Clinical Trial Report Cross-Over Studies Cytochrome P-450 CYP3A Inhibitors - adverse effects Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Fluconazole Fluconazole - adverse effects Fluconazole - pharmacokinetics Healthy Volunteers Humans Hyperlipidemia Male Medicine Medicine & Public Health Middle Aged Oncology Ovarian cancer Pharmacokinetics Pharmacology/Toxicology Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics Prostate cancer Ribose Transaminase Fluconazole CYP3A4 Drug–drug interaction (DDI) Fuzuloparib PARP inhibitor
ISSN:	0344-5704, 1432-0843, 1432-0843
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!